Most Awaited Q3 Sale is back. Upto 30% discount on every report.

Stem Cell Therapies – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2022 August 11
SKU : 953
180 pages
Report Summary
Table of Contents

Stem Cell Therapies

  • Stem cells are used in the replenishment of blood and immune systems. Apart from their use in the immuno-reconstitution, the stem cells have been reported to contribute in the tissue regeneration and as delivery vehicles in the cancer treatments.
  • Stem cells are progenitor cells that are unique in that they are unclassified cells that can modify to become virtually any kind of cell in the body (totipotent).
  • Because of the potential that stem cells can replace defective or damaged cells resulting from a variety of disorders and injuries, an increased focus is noticed leading to a range of new regenerative therapies.
  • Today, we can extract, artificially grow, and transplant them into the body to treat neurodegenerative and autoimmune disorders.
  • Prevailing pipeline candidates for cardiovascular indications are in preclinical development, with ~73% of stem cell pipeline therapies explicitly targeting cardiovascular indications.
  • Currently, there is a lack of big pharma investment in the application of stem cell therapy to cardiovascular clinical development, small biotech companies have undertaken most of the R&D efforts in this space.
  • Introduction of mesenchymal stem cells therapy is presaged as one of the most promising investigational approaches by the market research analysts.
  • The placental stem cells field is projected to grow at the exponential rate; owing to the global mount in the number of placental and cord banks conjugated with growing public awareness.
  • The surge in neurodegenerative diseases and massive investments in adult stem cell research are factors that are contributing to the market growth.
  • Most studies are in clinical phase trials, among which more percentage of studies are under early phase, phase1, phase 2 compared to phase 3 trails. NLA-101 of Nohla, MGTA-456 of Magenta Therapeutics are under phase 2 stage of development.
  • Gamida’s stem cell therapies are in late-stage of development raising expectations on the therapies to be available to patients in the foreseeable future.
  • Factors like public awareness affiliated to the therapeutic potential of stem cells; development of latest technologies for stem cell preservation, processing, and storage; increasing number of stem cell-based research and rising number of hematopoietic stem cell transplantations have led to the market growth of stem cell banking.
  • However, the high operational costs associated with, and stringent regulatory frameworks are expected to restrain the growth of the market.
Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
Request new version